Amphastar Pharmaceuticals (AMPH) Stock Forecast & Price Target

Compare

433 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMPH Analyst Ratings

Moderate Buy

2 Buy

3 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Amphastar

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMPH Stock 12 Month Forecast

Average Price Target

$30.75

▲(17.95% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Amphastar Pharmaceuticals in the last 3 months. The average price target is $30.75 with a high forecast of $34.00 and a low forecast of $25.00. The average price target represents a 17.95% change from the last price of $26.07.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","33":"$33","46":"$46","26.5":"$26.5","39.5":"$39.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,26.5,33,39.5,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.45,27.953846153846154,28.45769230769231,28.96153846153846,29.465384615384615,29.96923076923077,30.473076923076924,30.97692307692308,31.48076923076923,31.984615384615385,32.488461538461536,32.99230769230769,33.496153846153845,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.45,27.703846153846154,27.95769230769231,28.21153846153846,28.465384615384615,28.71923076923077,28.973076923076924,29.226923076923075,29.48076923076923,29.734615384615385,29.98846153846154,30.24230769230769,30.496153846153845,{"y":30.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.45,27.26153846153846,27.073076923076922,26.884615384615383,26.696153846153845,26.507692307692306,26.31923076923077,26.130769230769232,25.942307692307693,25.753846153846155,25.565384615384616,25.376923076923077,25.18846153846154,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.88,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.87,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.43,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.21,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$34.00

Average Price Target$30.75

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cerena Chen

Wells Fargo

$34

Buy

30.42%

Upside

Reiterated

12/17/25

Wells Fargo Reaffirms Their Buy Rating on Amphastar Pharmaceuticals (AMPH)

Serge Belanger

Needham

$34

Buy

30.42%

Upside

Reiterated

12/15/25

Amphastar Pharmaceuticals Receives Buy Rating Following FDA Approval of AMP-015

Glen Santangelo

Barclays

$30

Hold

15.07%

Upside

Initiated

12/08/25

Amphastar initiated with an Equal Weight at BarclaysAmphastar initiated with an Equal Weight at Barclays

Jason Gerberry

Bank of America Securities

Hold

―

Reiterated

11/07/25

Analysts Conflicted on These Healthcare Names: Amphastar Pharmaceuticals (NASDAQ: AMPH), Astrana Health (NASDAQ: ASTH) and Progyny (NASDAQ: PGNY)

David Amsellem

Piper Sandler

$25

Hold

-4.10%

Downside

Reiterated

11/07/25

Amphastar Pharmaceuticals (AMPH) Gets a Hold from Piper Sandler

Ekaterina Knyazkova

J.P. Morgan

$45→$30

Hold

15.07%

Upside

Downgraded

05/12/25

Analysts Offer Insights on Healthcare Companies: Astrana Health (NASDAQ: ASTH) and Amphastar Pharmaceuticals (NASDAQ: AMPH)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cerena Chen

Wells Fargo

$34

Buy

30.42%

Upside

Reiterated

12/17/25

Wells Fargo Reaffirms Their Buy Rating on Amphastar Pharmaceuticals (AMPH)

Serge Belanger

Needham

$34

Buy

30.42%

Upside

Reiterated

12/15/25

Amphastar Pharmaceuticals Receives Buy Rating Following FDA Approval of AMP-015

Glen Santangelo

Barclays

$30

Hold

15.07%

Upside

Initiated

12/08/25

Amphastar initiated with an Equal Weight at BarclaysAmphastar initiated with an Equal Weight at Barclays

Jason Gerberry

Bank of America Securities

Hold

―

Reiterated

11/07/25

Analysts Conflicted on These Healthcare Names: Amphastar Pharmaceuticals (NASDAQ: AMPH), Astrana Health (NASDAQ: ASTH) and Progyny (NASDAQ: PGNY)

David Amsellem

Piper Sandler

$25

Hold

-4.10%

Downside

Reiterated

11/07/25

Amphastar Pharmaceuticals (AMPH) Gets a Hold from Piper Sandler

Ekaterina Knyazkova

J.P. Morgan

$45→$30

Hold

15.07%

Upside

Downgraded

05/12/25

Analysts Offer Insights on Healthcare Companies: Astrana Health (NASDAQ: ASTH) and Amphastar Pharmaceuticals (NASDAQ: AMPH)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amphastar Pharmaceuticals

1 Month

xxx

Success Rate

4/6 ratings generated profit

Average Return

+5.73%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.73% per trade.

3 Months

xxx

Success Rate

2/6 ratings generated profit

Average Return

+2.57%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of +2.57% per trade.

1 Year

Bryce GeneronTR | OpenAI - 4o

Success Rate

2/6 ratings generated profit

Average Return

+2.57%

reiterated a buy rating 10 days ago

Copying Bryce Generon's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +2.57% per trade.

2 Years

xxx

Success Rate

2/6 ratings generated profit

Average Return

+2.57%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +2.57% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMPH Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMPH has received 6 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. AMPH average Analyst price target in the past 3 months is 30.75.

Each month's total comprises the sum of three months' worth of ratings.

AMPH Financial Forecast

AMPH Earnings Forecast

Next quarter’s earnings estimate for AMPH is $0.93 with a range of $0.80 to $1.00. The previous quarter’s EPS was $0.93. AMPH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AMPH has Performed in-line its overall industry.

AMPH Sales Forecast

Next quarter’s sales forecast for AMPH is $190.50M with a range of $179.78M to $195.40M. The previous quarter’s sales results were $191.84M. AMPH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AMPH has Performed in-line its overall industry.

AMPH Stock Forecast FAQ

What is AMPH’s average 12-month price target, according to analysts?

Based on analyst ratings, Amphastar Pharmaceuticals’s 12-month average price target is 30.75.

What is AMPH’s upside potential, based on the analysts’ average price target?

Amphastar Pharmaceuticals has 17.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMPH a Buy, Sell or Hold?

Amphastar Pharmaceuticals has a consensus rating of Moderate Buy which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.

What is Amphastar Pharmaceuticals’s price target?

The average price target for Amphastar Pharmaceuticals is 30.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $25.00. The average price target represents 17.95% Increase from the current price of $26.07.

What do analysts say about Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of AMPH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Amphastar Pharmaceuticals (AMPH) Stock Forecast & Price Target

AMPH Analyst Ratings

AMPH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amphastar Pharmaceuticals

AMPH Analyst Recommendation Trends

AMPH Financial Forecast

AMPH Earnings Forecast

AMPH Sales Forecast

AMPH Stock Forecast FAQ

Detailed List of Analyst Forecasts